A prospective cohort study of Bushenyijing granules Intervention in early-stage Alzheimer's Disease

Jiangsu Province Hospital of Chinese Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•1. Patients are diagnosed mild cognitive impairment due to Alzheimer's disease or dementia due to Alzheimer's disease meeting the criteria of National Institute on Aging-Alzheimer's Association workgroups(NIA-AA) on diagnostic guide lines for Alzheimer's disease(2011);
•2. Patients aged between 65 and 85 years old;
•3. Clinical Dementia Rating Scale(CDR) score i 0.5-2;
•4. Hachinski ischemic scale(HIS)4 ;
•5. Imaging evidencethe structural MRI image shows a disproportionate atrophy of the temporal and medial parietal lobes CSF biomarkers can be included, such as decreased A beta 42 or increased p-tau, T-tau;
•6. Syndrome differentiation of TCM indicates deficiency of kidney and spleen;
•7. Patients or their guardians voluntarily participate in the study and written the informed consent form.

•1. Patients failed to cooperate with Cognitive function test;
•2. Patients had a history of psychiatric drug or alcohol dependence for 6 months;
•3. Participating in other cognitive related clinical studies currently;
•4. Irritability;
•5. Excluding other diseases that cause cognitive decline, such as: Hypothyroidism, Parkinson's disease, stroke, TIA, intracranial hemorrhage, focal brain injury, brain tumor, positive pressure hydrocephalus, lewy body dementia, frontotemporal lobar degeneration or other mental disorders accompanied by depression and anxiety;
•6. Patients with severe diabetes or serious cardiovascular disease, cerebrovascular disease, liver disease, kidney disease, severe bone and joint disease and mental disorders.

发起方

Jiangsu Province Hospital of Chinese Medicine